| scholarly article | Q13442814 |
| P50 | author | Mathias O Senge | Q47839953 |
| Keith J. Flanagan | Q55999144 | ||
| Heba T Abdel-Mohsen | Q89653806 | ||
| P2093 | author name string | Mamdouh M Ali | |
| Hoda I El Diwani | |||
| Ahmed M El Kerdawy | |||
| Fatma A F Ragab | |||
| Mona A Abdullaziz | |||
| Abeer E E Mahmoud | |||
| P2860 | cites work | Cell signaling by receptor tyrosine kinases | Q24598357 |
| Tyrosine kinase - Role and significance in Cancer. | Q24791430 | ||
| Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? | Q27001584 | ||
| Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors | Q27673353 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Hepatocellular carcinoma: a review | Q28069290 | ||
| Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma | Q28075305 | ||
| Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 | ||
| Angiogenesis: an organizing principle for drug discovery? | Q29614538 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| New knowledge of the mechanisms of sorafenib resistance in liver cancer | Q33759933 | ||
| Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage | Q34144848 | ||
| Protein kinases as targets for anticancer agents: from inhibitors to useful drugs | Q34792836 | ||
| Crystal structure refinement with SHELXL. | Q35539543 | ||
| Sorafenib for treatment of hepatocellular carcinoma: a systematic review | Q36680204 | ||
| Sorafenib for the treatment of advanced renal cell carcinoma | Q36692604 | ||
| Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors | Q36723753 | ||
| The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling | Q37872771 | ||
| Review of angiogenesis in hepatocellular carcinoma | Q38188582 | ||
| FDA-approved small-molecule kinase inhibitors. | Q38480289 | ||
| Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes | Q38623447 | ||
| Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors | Q38683721 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives | Q38790512 | ||
| Synthesis, biological evaluation, and docking studies of new 2-furylbenzimidazoles as anti-angiogenic agents: part II. | Q39027159 | ||
| Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling | Q39375920 | ||
| Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors | Q39530608 | ||
| KLIFS: a structural kinase-ligand interaction database | Q40397851 | ||
| Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization | Q41992834 | ||
| VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis | Q42271421 | ||
| Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | Q42775676 | ||
| NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities | Q43116223 | ||
| A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis. | Q43196350 | ||
| Design, synthesis, conformational and molecular docking study of some novel acyl hydrazone based molecular hybrids as antimalarial and antimicrobial agents | Q44169873 | ||
| Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents | Q48261468 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| Regorafenib for the treatment of hepatocellular carcinoma. | Q54119748 | ||
| Kinases and cancer | Q54670763 | ||
| The Role of Angiogenesis in Hepatocellular Carcinoma | Q57053754 | ||
| Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors | Q57470962 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Bioactive glycoalkaloides isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells | Q61797064 | ||
| Treatment strategies for locally advanced hepatocellular carcinoma | Q64262622 | ||
| Characterization of amide bond conformers for a novel heterocyclic template of N-acylhydrazone derivatives | Q86046713 | ||
| Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of nov | Q90026420 | ||
| Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors | Q91711894 | ||
| New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma | Q92344153 | ||
| Properties of FDA-approved small molecule protein kinase inhibitors | Q92401801 | ||
| New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation | Q92973255 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P577 | publication date | 2020-02-11 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles | |
| P478 | volume | 25 |
Search more.